”And we want to do it again and again and again”
Approval of the diabetes drug Lyxumia is just the first step for Zealand Pharma. Read the interview with CEO David Solomon, in which he talks about the future plans for the company and explains why “small is beautiful and comfort kills”.
by Leonora Beck
The gloomy first day of the week became somewhat brighter for the mid-sized Danish biotech company, Zealand Pharma. The company’s drug darling, the GLP-1 Lyxumia, was finally approved for the European market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
